Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-02-24

Clinical Trial Update: Open-label Extension of the HOPE-2 Trial [Phase 2]

View source ↗

Summary

Open-label extension update for Capricor’s HOPE-2 Phase 2 trial in Duchenne muscular dystrophy, with results posted in February 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CAP-1002 (cardiosphere-derived cells)

Snippet

Sponsor: Capricor Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-24